Compare CANG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANG | MDWD |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 214.9M |
| IPO Year | 2018 | 2013 |
| Metric | CANG | MDWD |
|---|---|---|
| Price | $0.41 | $16.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.4M | 86.5K |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $428.72 | $48.92 |
| Revenue Next Year | $18.39 | $35.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $14.90 |
| 52 Week High | $5.75 | $22.51 |
| Indicator | CANG | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 42.38 |
| Support Level | $0.33 | $14.90 |
| Resistance Level | $0.50 | $18.49 |
| Average True Range (ATR) | 0.06 | 0.59 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 11.24 | 8.87 |
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.